The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron

President Donald Trump’s most-favored-nation drug pricing campaign reached its biggest political milestone after Regeneron Pharmaceuticals became the final company among 17 major drugmakers targeted by the White House to strike a pricing deal. The agreement requires Regeneron to lower Medicaid prices based on prices in other developed countries, align US prices for future medicines with […] The post The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron appeared first on the deep dive.